We studied the metabolism of 14,15-dehydro-leukotriene A % (14,15-dehydro-LTA % ) by human platelet leukotriene C % (LTC % ) synthase and polymorphonuclear leucocyte (PMNL) leukotriene A % (LTA % ) hydrolase. Metabolites were separated and identified using reversed-phase HPLC coupled to diode-array UV detection. Human platelets metabolize 14,15-dehydro-LTA % to 14,15-dehydro-LTC % with apparent kinetics identical with authentic LTA % . Metabolism to 14,15-dehydro-LTC % is inhibited by MK-886, a reported LTC % synthase inhibitor in human platelets, with a potency comparable with that shown by LTA % . In contrast, neither human red-blood-cell lysates nor human PMNL enzym-
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INTRODUCTION
Leukotrienes (LTs), namely leukotriene B % (LTB % ) and cysteinyl leukotrienes leukotriene C % (LTC % ), leukotriene D % and leukotriene E % , represent a family of potent, biologically active compounds. They are synthesized from the unstable epoxy intermediate leukotriene A % (LTA % ) through the action of two enzymes : LTA % hydrolase, which catalyses the formation of LTB % , and LTC % synthase, which conjugates glutathione and LTA % , giving rise to LTC % [1] . Synthesis of LTB % and LTC % can be carried out either within the same cell, which also contains the enzyme 5-lipoxygenase, catalysing the conversion of arachidonic acid into LTA % , or in different cells. This phenomenon, whereby a cell is able to transfer the unstable intermediate LTA % to a different cell, which carries out the final conversion into LTB % or LTC % , has been termed ' transcellular biosynthetic pathway of leukotrienes '. A number of examples supporting the importance of this pathway for LT biosynthesis have been reported over the last decade [2] [3] [4] .
LTA % hydrolase and LTC % synthase may represent potential independent targets for drug activity, and both enzymes have been cloned and sequenced [5] [6] [7] . Studies on the mechanismbased inactivation of the LTA % hydrolase by LTA % led to the identification of a potential site for irreversible binding of LTA % on LTA % hydrolase [8] . Several analogues of LTA % have been used by different groups to test the influence of structural modifications on the enzymic activity of LTA % hydrolase or LTC % synthase [9] [10] [11] [12] . We report on a novel LTA % analogue, tested both on human platelet LTC % synthase and on human erythrocyte and polymorphonuclear leucocyte (PMNL) LTA % hydrolase.
MATERIALS AND METHODS
Human blood (40 ml) was withdrawn from healthy donors that had not taken medications for at least 1 week ; it was collected into a 50 ml polypropylene centrifuge tube containing 5.7 ml of ACD (41 mM citric acid\100 mM sodium citrate\136 mM glucose) and carefully mixed. After centrifugation for 20 min at room temperature (RT) and 200 g, platelet-rich plasma was removed, re-acidified with 1 vol. of ACD and centrifuged for 15 min at RT and 1000 g. Pelleted platelets were resuspended with 5 ml of washing buffer (36 mM citric acid\5 mM glucose\ 5 mM KCl\2 mM CaCl # \1 mM MgCl # \103 mM NaCl, pH 6.5) containing 0.4 % (w\v) BSA and prostaglandin E " (final concentration 100 nM), according to Patscheke [13] . Platelets were further centrifuged for 15 min at RT and 400 g, and finally resuspended in PBS without Ca# + and Mg# + (PBS = ).
To sediment erythrocytes, the residual blood was diluted with 1 vol. of saline [0.9 % (w\v) NaCl] and 0n5 vol. of dextran T-500 [6 % (w\v) in saline]. The upper layer was centrifuged for 20 min at RT and 200 g, and the pellet subjected to erythrocyte lysis by gentle resuspension in 1 vol. of NaCl solution (0.2 %, w\v), followed by dilution with 1 vol. of a balancing solution [1.6 % (w\v) NaCl\0.2 % (w\v) sucrose].
PMNL were separated by centrifugation on Ficoll cushions (d l 1.077) for 30 min at RT and 400 g. PMNL were then washed twice with PBS = and resuspended in PBS = at a concentration of approx. 10( cell\ml.
Purified neutrophils and eosinophil-enriched cell preparations were obtained according to Koenderman et al. [14] . Briefly, PMNL were exposed to N-formylmethionyl-leucyl-phenylalanine (10 −) M) for 10 min at 37 mC in PBS = , in order to decrease the density of neutrophils, and then centrifuged over a discontinuous gradient of 1.082 and 1.100 g\ml Percoll. Neutrophils were recovered at the upper interface while the lower interface collected an enriched eosinophil preparation (10-25 % eosinophils, as assessed on cytocentrifugates stained with Giemsa). Platelets and PMNL were counted in a Burker chamber. The viability of PMNL was assessed by Trypan Blue dye exclusion, and was 90 % throughout the experiments. Erythrocytes from dextran sedimentation were diluted with sterile, 0.9 % (w\v) NaCl and centrifuged twice at RT and 200 g, discarding the supernatant. Red blood cells were lysed, adding an equal volume of distilled water for 20 s, and centrifuged at 4 mC and 100000 g. The supernatant was removed, filtered through a 0.45-µm Millipore filter and tested for LTA % hydrolase activity [15] .
LTA % and 14,15-dehydro-LTA % free acids were obtained through base-catalysed hydrolysis of corresponding methyl esters. Briefly, LTA % and 14,15-dehydro-LTA % methyl esters were dried under a stream of nitrogen and reconstituted in icecold acetone\0.25 M NaOH (4 : 1, v\v) ; hydrolysis was performed at room temperature for 60 min and the free acids obtained were added to human platelets (10) cells), to PMNL (10( cells) or to red-blood-cell lysates (5 mg of protein) at a final concentration of 0.1-10 µM. The purity of methyl esters was checked by normal-phase HPLC, using cyclohexane\ethyl acetate\triethylamine (99 : 0.5 : 1, by vol.) to isocratically elute a Lichrospher Si-100 column (4 mmi250 mm, 5 µm ; Merck) at a flow rate of 1 ml\min. Free acids were analysed for purity by reversed-phase HPLC (RP-HPLC) using acetonitrile\0.01 M borate buffer, pH 10 (4 : 6, v\v) to isocratically elute an Ultrasphere RP-18 column (4 mmi250 mm, 5 µm ; Beckman Analytical, Palo Alto, CA, U.S.A.) at a flow rate of 1 ml\min [16] .
UV absorbance was monitored at 280 nm and full UV spectra (240-340 nm) acquired at a scan rate of 0.5 Hz, using a diodearray UV detector (model 168, Beckman Analytical). The identities of methyl esters and free acids were assigned based on retention time and on-line UV absorbance spectra.
MK-886 (1-30 µM, DMSO solution) or RP 64966 [20 µM ethanol\1 M HCl (2 : 1, v\v)] was added to cell or cell-lysate preparations 5 min before the LTA % or 14,15-dehydro-LTA % . For studies on the irreversible inactivation of LTA % hydrolase, human PMNL were preincubated for 5 min at 37 mC with 14,15-dehydro-LTA % (0.1-10 µM) or with solvent alone, centrifuged twice at RT and 200 g, resuspended in 1 ml of PBS, and finally added with LTA % (1 µM). Incubations were terminated after 1 min by addition of 2 vol. of ice-cold methanol containing the HPLC internal standard prostaglandin B # (LTA % experiments) or prostaglandin B " (14,15-dehydro-LTA % experiments). For glutathione S-transferase activity evaluation, washed human platelets were resuspended in lysis buffer [0.05 M phosphate buffer (pH 7.4)\0.1 M NaCl\2 mM EDTA\aprotinin (0.1 units\ml)\pepstatin (1 µg\ml)\leupeptin (1 µg\ml)] at a concentration of (3-5)i10* ml −" , and sonicated for 4i15 s on ice, using a sonifier (power setting 5 ; model XL ; Heat Systems, Farmingdale, NY, U.S.A.), equipped with a microtip. Disrupted platelets were centrifuged for 20 min at 4 mC and 12 000 g and supernatant, representing cytosol and microsomal membranes, was tested for enzymic activity.
Proteins were quantified spectrophotometrically using Coomassie Protein Assay Reagent (Pierce, Rockford, IL, U.S.A.), with BSA as standard.
Glutathione S-transferase (EC 2.5.1.18) in platelet lysates (100 µg of protein) was assayed spectrophotometrically at 340 nm in a reaction system containing 1 mM glutathione, 1 mM 1-chloro-2,4-dinitrobenzene (Sigma), 5 % (v\v) ethanol and 0.1 M sodium phosphate, pH 6.5, at 25 mC [17] . The increase in absorbance at 340 nm was monitored for 3 min using a Jasco spectrophotometer (V-530, Tokyo, Japan), in the presence or absence of MK-886 (30 µM). Results were expressed as nmol of 1-chloro-2,4-dinitrobenzene-glutathione conjugate formed\ min per mg of protein, using an absorption coefficient of 9600 mol:l −" :cm −" at 340 nm.
LTA % -derived metabolites were analysed by RP-HPLC coupled to diode-array UV detection, as described previously [18] . IC &! was evaluated by non-linear regression using the computer program Allfit QB [19] .
Eicosanoids were purchased from Cayman Chemical Co. (Ann Arbor, MI, U.S.A.). 14,15-Dehydro-LTA % methyl ester was synthesized as described previously [20] . HPLC-grade solvents were obtained from Merck. Type I ' plus ' water was obtained using a MilliQ Plus water purifier (Millipore, Molsheim, France), fed with double-distilled water.
RESULTS
In agreement with a preliminary report [20] , RP-HPLC analysis of incubates of human platelets exposed to 14,15-dehydro-LTA % (1 µM) revealed a chromatographic profile similar to that observed using authentic LTA % , except all the chromatographic peaks moved to shorter retention times. The peak corresponding to 14,15-dehydro-LTC % showed a unique UV absorption spectrum, with λ max at 279 nm and shoulders at 269 and 290 nm, and was structurally characterized by controlled metabolism and electrospray tandem mass spectrometry, collision induced dissociation [20] .
In order to rule out the possibility that the conversion of 14,15-dehydro-LTA % into 14,15-dehydro-LTC % was the result of glutathione S-transferase activity, rather than the unique LTC %
synthase, we tested the effect of compound MK-886, which we recently reported was an inhibitor of the human platelet LTC % synthase [21] . MK-886 dose-dependently inhibited the formation of 14,15-dehydro-LTC % with an IC &! of 4.7 µM (Table 1) , which is similar to that observed using authentic LTA % as substrate. A glutathione S-transferase activity of 26.6p9.0 nmol\min per mg of protein (meanpS.E.M., n l 3) was evaluated in lysed human platelets, and was only slightly affected (22p9 % inhibition) by the presence of MK-886 at a concentration (30 µM) resulting in complete inhibition of 14,15-dehydro-LTC % formation in intact platelets.
The affinity of 14,15-dehydro-LTA % for LTC % synthase was very similar to that observed with authentic LTA % (Figure 1 ) : apparent K m and V max of 1.6 µM and 200 pmol\min per 10) platelets were measured, to be compared with 2 µM and 200 pmol\min per 10) platelets respectively for LTA % . Addition of LTA % to lysed erythrocytes resulted in the formation of LTB % ; this was completely prevented by preincubation with 20 µM RP 64966, a specific inhibitor of LTA % hydrolase [22] . No difference was observed between the chromatographic profiles obtained in the presence or in the absence of the inhibitor when 14,15-dehydro-LTA % was used, indicating lack of metabolism by the red-blood-cell LTA % hydrolase ( Figure 2 ). 
Figure 2 RP-HPLC separation of LTA 4 and 14,15-dehydro-LTA 4 metabolites after incubation with red blood cell lysates
Red-blood-cell lysates (5 mg of protein) were incubated for 1 min with (A) 1 µM LTA 4 and (B) 1 µM 14,15-dehydro-LTA 4 . LTB 4 was identified by on-line UV-spectrum analysis and retention times of synthetic standards. The chromatographic profile obtained with 14,15-dehydro-LTA 4 was not modified by the presence of 20 µM RP-64966, a specific LTA 4 hydrolase inhibitor, and was identical with that obtained in the absence of red-blood-cell lysate. Significant peaks eluting before and after the internal standard, prostaglandin B 1 (PGB 1 ), represent the products of nonenzymic hydrolysis of 14,15-dehydro-LTA 4 . A.U., absorbance units. were identified by on-line UV-spectrum analysis and retention times of synthetic standards. 14,15-Dehydro-LTC 4 was identified by on-line UV-spectrum analysis and retention times of mass spectrometry-characterized platelet metabolites. A.U., absorbance units. 3A), in agreement with previously published data [18, 23] . No significant metabolism was observed on addition of up to 10 µM 14,15-dehydro-LTA % , except for minor amounts of 14,15-dehydro-LTC % ( Figure 3B ). In order to test if eosinophil contamination could account for the 14,15-dehydro-LTC % production by PMNL, highly purified neutrophils and eosinophilenriched preparations were checked. The results obtained showed that neutrophils were not able to enzymically process 14,15-dehydro-LTA % to any extent, whereas significant amounts of 14,15-dehydro-LTC % were synthesized by eosinophil-enriched preparations (Figure 4) .
Preincubation of neutrophils with 14,15-dehydro-LTA % (0.1-10 µM) caused irreversible inactivation of LTA % hydrolase, with an IC &! of 0.73 µM ( Table 2) .
DISCUSSION
The results obtained using a unique LTA % analogue show that substitution of a double with a triple bond at C-14,15 leaves a substrate suitable for metabolism by LTC % synthase. The resulting 14,15-dehydro-LTC % analogue has been previously characterized by RP-HPLC with on-line UV spectroscopy, enzymic conversion and mass spectrometry.
LTC % synthase, as shown by recent cloning and expression [5, 6, 24] , does not belong to the family of glutathione S-transferases, but presents significant similarity to another protein involved in leukotriene metabolism, namely the ' five lipoxygenase activating protein '. Further supporting this observation, a known 5-lipoxygenase-activating-protein inhibitor, compound MK-886, was reported to dose-dependently inhibit cloned, expressed LTC % synthase. In agreement with these data, we showed recently that MK-886, as well as a different, structurally unrelated 5-lipoxygenase-activating-protein inhibitor, was able to modulate human platelet LTC % synthase [21] . Inhibition of 14,15-dehydro-LTA % metabolism by human platelets on preincubation with compound MK-886, provides pharmacological identification of LTC % synthase as the enzymic activity responsible for the synthesis of the observed 14,15-dehydro-LTC % analogue. A previous report had shown that saturation of the 14,15 double bond of LTA % did not affect metabolism by purified guinea-pig LTC % synthase [9] ; in contrast, later evidence pointed to significant differences in substrate specificity between human platelet and guinea-pig LTC % synthase. Using the guinea-pig enzyme, LTA % methyl ester showed a V max that was 4-fold higher than that for LTA % , whereas the same substrate presented a V max that was 14-fold lower than for LTA % using human platelet LTC % synthase [10] . Another LTA % analogue, 14,15-LTA % , was found not to be processed by the human platelet LTC % synthase, but still provided a good substrate for the guinea-pig enzyme, with a V max of twice that for LTA % . In the present paper we provide evidence that 14,15-dehydro-LTA % represents a substrate that is indistinguishable from authentic LTA % by human LTC % synthase. Therefore modifications of the lipophilic chain of LTA % do not affect either binding or catalytic conversion by LTC % synthase, thus providing additional information on the structural requirements for interactions with this biologically relevant enzyme.
14,15-Dehydro-LTA % was not enzymically converted by human PMNL or red-blood-cell LTA % hydrolase. Furthermore, preincubation with 14,15-dehydro-LTA % before addition of LTA % resulted in potent, irreversible inhibition of LTA % hydrolase activity. These data support results obtained with leukotriene A $ and rat neutrophils, showing that the double bond at C-14,15 represents a critical feature for the enzymic conversion carried out by the specific LTA % hydrolase. Interaction with the binding site of the enzyme does not appear to be affected by the modification of the ∆"% double bond. In fact leukotriene A $ and 14,15-dehydro-LTA % , as well as authentic LTA % , irreversibly bind to human LTA % hydrolase preventing further enzymic activity. On LTA % , the cis geometry of the double bond at C-14,15 might impose a specific orientation of the lipophilic chain, resulting in correct interaction of the conjugated system with the enzyme.
Reviewing data obtained with different LTA % analogues shows that the overall structure of the lipophilic chain seems to be less important than the presence of the 14,15 double bond in connection with the possibility of metabolism by the LTA % hydrolase : leukotriene A & , possessing an additional double bond at C-17,18 is still efficiently metabolized to leukotriene B & , although the apparent V max is severalfold lower than that for authentic LTA % [12] . Interestingly, leukotriene A & is also a suitable substrate for LTC % synthase, but enzymic conversion appears to be 20-fold less efficient than with the specific substrate LTA % . In conclusion, we found that the substitution with a triple bond of the double bond at C-14,15 of LTA % does not affect the metabolism by human platelet LTC % synthase, but completely prevents metabolism by erythrocyte and PMNL LTA % hydrolase. These data provide additional information on the structural requirements for binding and metabolism by these two important enzymes. Furthermore, the observation of a preserved biological activity by 14,15-dehydro-LTC % [20] suggests that 14,15-dehydro-LTA % may represent a valuable tool for the study of the pathophysiological role of transcellular synthesis of cysteinyl leukotrienes in complex organ systems [25] .
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